Arena Pharmaceuticals (FRA:RN3N) Other Long Term Assets : €31.26 Mil (As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Other Long Term Assets?

Arena Pharmaceuticals's other long-term assets for the quarter that ended in Dec. 2021 was €31.26 Mil.

Arena Pharmaceuticals's quarterly other long-term assets declined from Jun. 2021 (€32.72 Mil) to Sep. 2021 (€31.96 Mil) but then stayed the same from Sep. 2021 (€31.96 Mil) to Dec. 2021 (€31.26 Mil).

Arena Pharmaceuticals's annual other long-term assets increased from Dec. 2019 (€16.31 Mil) to Dec. 2020 (€24.10 Mil) and increased from Dec. 2020 (€24.10 Mil) to Dec. 2021 (€31.26 Mil).

Arena Pharmaceuticals Other Long Term Assets Historical Data

The historical data trend for Arena Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Other Long Term Assets Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Other Long Term Assets

Get a 7-Day Free Trial

3.06

106.05

16.31

24.10

31.26

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Other Long Term Assets	Get a 7-Day Free Trial															24.10	34.61	32.72	31.96	31.26

Arena Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines